Pattern Health Closes $3.3M Series A to Expand Digital Health Research and Clinical Implementation Capabilities
Pattern Health, a digital health company, today announced the closing of a $3.3 million series A funding round. The round was led by the Dr. William H. Joyce Family Office, with contributions from existing investors Cofounders Capital, The Launch Place, and Triangle Tweener Fund. Allen A. Spizzo of the Joyce Family Office has joined the board of directors.
Pattern will use the new capital to fuel the company’s growth and ability to deliver on its mission–accelerating digital health innovation from research to real-world impact. The company’s unique no-code digital health platform helps partners more quickly and cost-effectively research and develop new ways to improve care and, once proven effective, deliver their innovations at scale to improve more patients’ lives.
“This is an exciting time for Pattern, our partners, and the patients who benefit from the solutions being developed and deployed on our platform,” notes Pattern’s CEO and Co-Founder, Ed Barber. “We are thankful to the academic medical centers, health systems, and leading researchers that have put their trust in Pattern as their digital health innovation partner of choice. Our series A will enable us to more rapidly improve our technology, expand our footprint, and benefit more people at a greater scale.”
Pattern’s capabilities are enabled by a no-code digital health platform that provides the interoperability, scalability, security, and compliance needed to create and distribute digital health programs. The company currently powers research across a wide range of conditional areas at 12 of the top 20 academic medical centers in the US as measured by NIH funding.
“Pattern has made an impressive impact to date, and we are excited by the opportunity to scale the business,” said Mr. Spizzo of the Joyce Family Office. “Pattern’s no-code platform is a game-changer for healthcare researchers and innovators, and the company solves an unmet need by providing a pathway for effective digital health programs to reach patients quickly.”
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more